MEDIVIR AB – INTERIM REPORT JANUARY – MARCH 2021
Financing secured to bring the MIV-818 study into the next phaseJanuary – MarchFinancial summary for the quarter · Net turnover amounted to SEK 9.9 (7.3) million. · The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -7.2 (-20.7) million. Basic and diluted earnings per share amounted to SEK -0.18 (-0.96) and SEK -0.18 (-0.96) respectively. · Cash flow from operating activities amounted to SEK -1.5 (-16.6) million. · Liquid assets and short-term investments at the end of the period amounted to SEK 269.3 (116.6) million. Significant events